A Double-Blind, Randomized, Placebo-Controlled, Single- And-Multiple-Dose Study to Evaluate the Safety, PK, and PD of CRN00808 in Healthy Volunteers and to Determine the Effect of CRN00808 on Midazolam PK
Phase of Trial: Phase I
Latest Information Update: 06 Sep 2018
At a glance
- Drugs CRN-00808 (Primary) ; CRN-00808 (Primary) ; Midazolam
- Indications Acromegaly
- Focus Adverse reactions; First in man
- Sponsors Crinetics Pharmaceuticals
- 27 Aug 2018 Status changed from recruiting to completed.
- 20 Mar 2018 Results from the single-dose arm part of this trial (n=8/cohort), presented at The 100th Annual Meeting of the Endocrine Society.
- 12 Mar 2018 According to a Crinetics Pharmaceuticals media release, data from this trial will be presented at the upcoming ENDO 2018, the Annual Meeting of the Endocrine Society.